Jazz Pharmaceuticals has doubled in the past year, yet the valuation checks send a more muted signal, with the stock screening as undervalued on earnings multiples but only showing a mixed overall value score. For investors, the question now is whether the recent rally has already captured much of the good news around the company.

• Over the past 12 months, Jazz Pharmaceuticals has delivered a return of about 100%, which puts the recent share price near the upper end of its one year range and raises the bar for further gains.
• The recent U.S. approval of Ziihera regimens for HER2 positive gastroesophageal adenocarcinoma can support sentiment on Jazz Pharmaceuticals, while the planned US$1.0b exchangeable notes offering may add balance sheet and dilution concerns that weigh on how investors value the equity.
• According to Simply Wall St's composite checks, Jazz Pharmaceuticals carries a mixed value profile, with the stock screening as undervalued on several multiples but not as a clear bargain overall. This is reflected in its value score of 4.0.

The issue now is whether Jazz Pharmaceuticals' current price still leaves enough valuation upside to compensate for the risks around its pipeline, capital structure and future cash flows.

Compare Jazz Pharmaceuticals' sharp 100.3% one-year gain and mixed value score with a curated list of other stocks that also screen as undervalued using the 51 high quality undervalued stocks.

Does Jazz Pharmaceuticals Look Undervalued on Earnings?

The P/E multiple suits Jazz Pharmaceuticals because the company reports positive earnings that can be compared directly with industry peers. On this basis, Jazz Pharmaceuticals currently trades on a P/E of about 17.2x. That is close to the broader pharmaceuticals industry average of 16.8x, yet it is well below the peer group average of 29.8x. This suggests investors are assigning a lower earnings multiple than many similar stocks receive.

The fair P/E ratio derived from the model is 24.7x, which is higher than both the current multiple and the wider industry average. This gap indicates that Jazz Pharmaceuticals screens as undervalued on earnings, given its mix of growth drivers, margins, size and risk. Despite the recent FDA approval for Ziihera regimens influencing the story around its pipeline, the current P/E still prices the stock at a discount to the level implied by this framework.

On the P/E multiple, Jazz Pharmaceuticals stock appears undervalued relative to what the model suggests would be a fair earnings-based valuation.

The Jazz Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Jazz Pharmaceuticals valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth significantly more or less than today’s price, and each one links a specific fair value to a clear story about Jazz Pharmaceuticals' potential catalysts and key risks so you can see over time which scenario is lining up with reality.

Community views on Jazz Pharmaceuticals are split, with one side focused on the breadth of new products and the other on how much risk the current price already reflects.

Bull case: 11% undervalued

"Recent acquisition of Chimerix and other disciplined corporate development initiatives are diversifying Jazz's portfolio, extending patent life on new assets, and reducing reliance on legacy products..."

Bear case: 17% overvalued

"Revenue and margins face threats from upcoming patent expirations, generic competition, and global pricing pressures, especially in the sleep and rare disease franchises..."

Do you think there's more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Jazz Pharmaceuticals screens as undervalued on key earnings multiples, but the broader valuation checks are only mixed. That combination suggests the current discount could either be a cushion against risks around the pipeline and balance sheet, or a sign that the market is already pricing those risks in. The crux for investors is whether Jazz Pharmaceuticals can sustain earnings strength and manage patent, competition and funding pressures well enough for the P/E multiple to move closer to peers rather than stay anchored where it is.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.